Professional Documents
Culture Documents
Pregabalin U Terapiji Pacijenata Sa Generalizovanim Anksioznim Poremećajem - Pilot Istraživanje: Prikaz Serije Pacijenata
Pregabalin U Terapiji Pacijenata Sa Generalizovanim Anksioznim Poremećajem - Pilot Istraživanje: Prikaz Serije Pacijenata
makoterapija
na XIII Kongresu Udruženja psihijatara
Srbije
99
UVOD efikasnost, a nema neželjena dejstva koja
mogu da kompromituju tretman [5,6].
Generalizovani anksiozni poremećaj Pored toga, treba da se obrati pažnja na
karakteriše stanje intenzivne i dugotrajne eventualno postojanje komorbidih obo-
anksioznosti koja se manifestuje pato- ljenja (pre svega depresije), ali i na prak-
loškom brigom, strepnjom, iščekivanjem tične aspekte – kao što su iskustva sa te-
negativnog događaja, s jedne strane, i rapijom, dostupnost terapije i lekara za
uznemirenošću i napetošću, s druge buduće kontrole, ekonomske mogućnosti
strane [1,2]. Dakle, prvi element psiho- pacijenta, preference samog pacijenta i
patologije generalizovanog anksioznog slično.
poremećaja je pojava brige/anksioznosti Što se tiče farmakoterapije, na osnovu
oko problema svakodnevnog života. kliničkog iskustva i na osnovu rezultata
Drugi osnovni element psihopatologije kliničkih studija, a na bazi potvrđene
koji karakteriše ovaj poremećaj je stanje efikasnosti i najbenignijeg profila neže-
intenzivne napetosti i uznemirenosti pri ljenih dejstava, preporuka je da se paci-
čemu se javljaju somatski simptomi an- jenti sa generalizovanim anksioznim po-
ksioznosti. Sve ovo za obolelog pred- remećajem tretiraju nekim lekom iz
stavlja značajnu tegobu i uzrokuje pro- grupe SSRI antidepresiva (citalopram,
bleme u svakodnevnom funkcionisa- escitalopram, fluoksetin, paroksetin, ser-
nju. tralin), nekim lekom iz grupe iz grupe
Generalizovani anksiozni poremećaj SNRI antidepresiva (duloksetin ili ven-
se vrlo često sreće, kako u opštoj tako i lafaksin) ili pregabalinom, ukoliko ne
u kliničkoj populaciji, a smatra se da je postoje simptomi komorbidne depresije
jedan od najučestalijih anksioznih pore- [5,6,7].
mećaja. Istraživanja ukazuju da se pre- Pregabalin se pokazao kao izuzetno
valenca generalizovanog anksioznog po- efikasan lek u terapiji pacijenata sa ge-
remećaja u opštoj populaciji kreće u ra- neralizovanim anksioznim poremećajem.
Engrami l vol. 38 l april-jun 2016. l br. 2
104
USE OF PREGABALIN Abstract
backgraund: The efficacy of pregabalin
in patients with generalized anxiety di-
FOR THERAPY OF
PATIENTS WITH sorder (GAD) is shown in several control-
led clinical studies but there is a lack of
GENERALISED ANXIETY studies of pregabalin efficacy in routine
DISORDER – PILOT clinical practice. The aim of this paper is
to show the effectiveness of pregabalin
INVESTIGATION REVIEW therapy in GAD patients in everyday cli-
nical practice. METHOD: Case serial of
consecutive patients with diagnosis of
OF CASE STUDIES
GAD who were treated with pregabalin.
The sample comprised of patients from
Milan Latas 1,2 Counseling center for mental health in
Suzana Perović 3 Kragujevac who were treated from 2014
to 2016. The sample consisted of 57 pa-
Vladimir Janjić 4
tients. They have had diagnosis of GAD
Branislav Radmanović 4 and all of them were treated with prega-
balin. 14 (24.6%) patients were treated
with SSRI antidepressants, also. Clinical
severity was assessed with GAD-7 inven-
tory before the treatment and one month
after the beginning of it. GAD-7 assess 7
main dimensions of GAD. The overall
score of the GAD-7 indicate the severity
1 Medicinski fakultet, Univerzitet u of GAD. RESULTS: The main score of
Beogradu, Beograd, Srbija GAD-7 before the treatment was 16,46
2 Klinika za psihijatriju, Klinički centar (SD=3,17) in the range from 10 to 21. The
Srbije, Beograd, Srbija main score of GAD-7 after one month of
3 Savetovalište za mentalno zdravlje treatment was 8,71 (SD=4,03) in the range
from 3 to 18. The main value of the diffe-
rapy
a Suzana Perović je oržala honorisana
predavanja za kompaniju Pfizer.
105
Literatura
1 Međunarodna klasifikacija bolesti – 10. revi- disorder: a 4-week, multicenter, double-
zija. Beograd: Savremena administracija; blind, placebo-controlled trial of pregabalin
1996. and alprazolam. Arch Gen Psychiatry.
2 American Psyciatric Association. Diagnostic 2005; 62(9):1022-30.
and statistical manual of mental disorders 12 Feltner DE, Crockatt JG, Dubovsky SJ,
(5th ed.). Arlington, VA: American Psychia- Cohn CK, Shrivastava RK, Targum SD, Liu-
tric Publishing; 2013. Dumaw M, Carter CM, Pande AC. A rando-
3 Wittchen HU. Generalized anxiety disorder: mized, double-blind, placebo-controlled, fi-
prevalence, burden, and cost to society. xed-dose, multicenter study of pregabalin in
Depression and Anxiety 2002; 16:162–71. patients with generalized anxiety disorder. J
4 Kessler RC, Keller MB, Wittchen HU. The Clin Psychopharmacol. 2003; 23(3):240-9.
epidemiology of generalized anxiety disor- 13 Latas M, Janjić V, Milovanović S. The use
der. Psychiatr Clin North Am. 2001; of Pregabalin in the treatment of patients
24(1):19-39. with generalized anxiety disorder. Engrami.
5 Katzman MA, Bleau P, Blier P, et al. Cana- 2013; 35(1-2): 73-80.
dian clinical practice guidelines for the ma- 14 Spitzer RL, Kroenke K, Williams JB, Löwe
nagement of anxiety, post-traumatic stress B. A brief measure for assessing generali-
and obsessive-compulsive disorders. BMC zed anxiety disorder: the GAD-7. Arch In-
Psychiatry 2014; 14 (Suppl. 1). tern Med 2006; 166(10):1092–7.
6 Baldwin DS, Anderson IM, Nutt DJ. Evi- 15 Löwe B, Decker O, Müller S, Brähler E,
dence-based pharmacological treatment of Schellberg D, Herzog W, Herzberg PY. Vali-
anxiety disorders, post-traumatic stress di- dation and standardization of the Generali-
sorder and obsessive-compulsive disorder: zed Anxiety Disorder Screener (GAD-7) in
A revision of the 2005 guidelines from the the general population. Med Care. 2008;
British Association for Psychopharmaco- 46(3):266–74.
logy. J Psychopharmacol 2014; 28:403–39. 16 Baldwin DS, Schweizer E, Xu Y, Lyndon G.
7 Klinički centar Srbije. Klinički algoritmi. Beo- Does early improvement predict endpoint
grad; 2010. response in patients with generalized an-
8 Montgomery SA, Tobias K, Zornberg GL, xiety disorder (GAD) treated with pregaba-
Kasper S, Pande AC. Efficacy and safety of lin or venla faxine XR? Eur Neuropsyc-
pregabalin in the treatment of generalized hopharmacol. 2012; 22(2):137-42.
anxiety disorder: a 6-week, multicenter, ran- 17 Cvjetkovic-Bosnjak M, Soldatovic-Stajic B,
domized, double-blind, placebo-controlled
Engrami l vol. 38 l april-jun 2016. l br. 2
Babovic S, Boskovic K, Jovicevic M. Prega-
comparison of pregabalin and venlafaxine. balin versus sertraline in generalized an-
J Clin Psychiatry 2006; 67:771-82. xiety disorder. An open label study. Eur Rev
9 Kasper S, Herman B, Nivoli G, Van Amerin- Med Pharmacol Sci 2015; 19(11):2120-4.
gen M, Petralia A, Mandel FS, Baldinetti F,
Bandelow B. Efficacy of pregabalin and
venlafaxine-XR in generalized anxiety di-
sorder: results of a double-blind, placebo-
controlled 8-week trial. Int Clin Psychophar-
macol 2009; 24:87-96.
10 Lydiard RB, Rickels K, Herman B, Feltner
DE. Comparative efficacy of pregabalin and
benzodiazepines in treating the psychic
and somatic symptoms of generalized an-
xiety disorder. Int J Neuropsychopharmacol
Milan Latas
2010: 13:229-41.
Klinika za psihijatriju KCS
11 Rickels K, Pollack MH, Feltner DE, Lydiard Pasterova 2, Beograd
RB, Zimbroff DL, Bielski RJ, Tobias K, Tel: +381 11 366 2090
Brock JD, Zornberg GL, Pande AC. Prega- Fax: + 381 11 2645 543
balin for treatment of generalized anxiety e-mail: latasm@eunet.rs
106